Bristol Myers Squibb’s phase 3CheckMate -274 trial of Opdivo in patients with high-risk, muscle-invasive urothelial carcinoma meets primary endpoionts: Princeton, New Jersey Sat ...
Bristol Myers Squibb today announced that CheckMate -274, a pivotal Phase 3 trial evaluating Opdivo after surgery in patients with high-risk, muscle-invasive urothelial carcinoma, met its primary ...
PRINCETON, N.J.--(BUSINESS WIRE)--$BMY #BMS--Bristol Myers Squibb (NYSE: BMY) today announced three-year follow-up results from the Phase 3 CheckMate -274 trial ...
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or ...
SAN FRANCISCO — New findings lend further support to adjuvant nivolumab (Opdivo) as a standard of care for patients with metastatic urothelial cancer. Extended follow-up data from the phase 3 ...
Longer-term follow-up of the CheckMate-274 trial confirmed that treatment with the anti-PD-1 therapy nivolumab (Opdivo) after surgery helped reduce cancer recurrence in patients with muscle-invasive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results